Capital Fund Management S.A. Intellia Therapeutics, Inc. Call Options Transaction History

Capital Fund Management S.A.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	SELL	$20.02 - $27.22 $1.06 Million - $1.45 Million	-53,100 Reduced 54.69%	44,000 $984,000
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $469,254 - $646,160	19,700 Added 25.45%	97,100 $2.67 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $1.22 Million - $1.7 Million	52,600 Added 212.1%	77,400 $2.36 Million
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $784,176 - $1.14 Million	24,800 New	24,800 $784,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $922M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.